CJCJ

CJ's H1 2026 profit has nearly disappeared on a trailing basis, while the share price has fallen about a third over the past year.

CJ is a Korean holding company spanning food, biotech, logistics and retail, and entertainment. Trailing revenue of about ₩46.3T is still roughly in line with 2025, but trailing net income is only about ₩47B, compared with ₩143B in 2025 and ₩275B in 2021. The shares closed at ₩115,400 on 26 October 2026, near the 52-week low of ₩111,600.

What stands out

• Trailing operating income is about ₩2.4T with a 5.1% operating margin, down from 5.6% in 2025, but net income falls to roughly ₩47B and net margin to 0.1%.
• Trailing ROE is 0.9% and liabilities are 176.1% of equity, with borrowings of about ₩9.0T against cash of about ₩2.2T.
• The company's model-based fair value estimate is ₩15,384 (bear ₩10,256, bull ₩21,537), which is far below the current price; the data gives no basis for how that model was built beyond its method and date, so treat it with caution.
• Trailing P/E is 71.7 because earnings are so small, while P/B is 0.6 and dividend yield is 2.9%.
• Recent filings include several debt guarantee decisions for subsidiaries, a lawsuit filing or ruling, and a half-year report, and foreign ownership rose from 17.1% to 19.4% over about 60 days.

What to watch

• The next results release and whether earnings recover from the trailing net income level.
• Further filings on debt guarantees for subsidiaries and the outcome of the lawsuit disclosures, since the data does not give their size or details.
• Debt levels relative to cash and the pace of free cash flow, which was about ₩2.8T on a trailing basis.